Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line

Abstract

p38 mitogen-activated protein kinase (MAPK) belongs to the MAPK superfamily, phosphorylating serine and/or threonine residues of the target proteins. The activation of p38 MAPK leads to cell growth, differentiation, inflammation, survival or apoptosis. In this study, we tested the effect of two highly specific and potent inhibitors of p38 MAPK (namely, SB203580 and SB202190) on human breast cancer cell line MDA-MB-231 to elucidate the controversial role of p38 MAPK on cell proliferation and/or cell migration/metastasis further. It was determined that the IC value of SB203580 was 85.1 µM, while that of SB202190 was 46.6 µM, suggesting that SB202190 is slightly more effective than SB203580. To verify the effect of each inhibitor on cell proliferation and cytotoxicity, the cells were treated with various doses of SB203580 and SB202190 and examined using iCELLigence system. No significant effect of 1 and 5 µM of both inhibitors were seen on cell proliferation as compared to the DMSO-treated control cells for up to 96 h. On the other hand, both SB203580 and SB202190 significantly prevented cell proliferation at a concentration of 50 µM. SB202190 was again more effective than SB203580. Afterwards, we tested the effect of each inhibitor on cell migration using wound assay. Both SB203580 and SB202190 significantly reduced cell migration in a time-dependent manner at a concentration of 50 µM. However, interestingly it was observed that a low and noncytotoxic dose of 5 µM of SB203580 and SB202190 also did cause significant cell migration inhibition at 48 h of the treatment, corroborating the fact that p38 MAPK pathway has a critical role in cell migration/metastasis. Then, we tested whether each p38 MAPK inhibitor has any effect on cell adhesion during a treatment period of 3 h using iCELLigence system. A concentration of only 50 µM of SB202190 reduced cell adhesion for about 1.5 h (p < 0.001); after that period of time, cell adhesion in 50 µM SB202190-treated cells returned to the level of the control cells. To determine the mechanism of growth and cell migration inhibitory effects of p38 MAPK inhibitors, the activation/inactivation of various proteins and enzymes was subsequently analyzed by PathScan Intracellular Signaling Array kit. The ERK1/2 phosphorylation level was not modified by low concentrations (1 or 5 µM) of SB202190 and SB203580; while a high concentration (50 µM) of both inhibitors caused significant reductions in the ERK1/2 phosphorylation. In addition, it was determined that both p38 MAPK inhibitors caused significant increases on the Ser15 phosphorylation of mutant p53 in MDA-MB-231 under these experimental conditions; while SB202190 was more potent than SB203580.

Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer

“…Targeting KIF20A with more selective and potent small molecule inhibitors may be an effective therapeutic strategy for a wide variety of breast cancers. The newly developed, potent KIF20A inhibitor, BKS0349, was recently reported to suppress KIF20A ATPase activity at levels 2-10-fold greater than paprotrain in various cancer cell lines and in a xenograft mouse model without noticeable variation (48,49). Further preclinical studies investigating KIF20A inhibitors are crucial for the development of novel molecular targeted drugs that can be used to treat highly malignant breast cancers, such as TNBC.…”

Cadmium Induces Migration of Colon Cancer Cells: Roles of Reactive Oxygen Species, P38 and Cyclooxygenase-2

“…In fact, elevated levels of phosphorylated p38 have been associated with various malignancies [69]. A recently published study shows that p38 MAPK is involved in the migration of human breast cancer cells [70]. A positive association has been reported between high endogenous p38 MAPK activity and cancer cells invasiveness [71].…”

Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets

“…A recent paper investigating the contribution of CCL21/CCR7 signaling in lymph node metastasis reported the same results and deduced that p38 upregulation is involved in CCL21‐induced PCa cell migration [ 67 ]. Another report recorded the same inhibitory effect of SB203580 on cell migration of breast cancer cell lines [ 68 ] and human PCa cell lines [ 66 ].…”